TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years, male or female~* Signed written informed consent~* Patients with histologically confirmed diagnosis of colorectal cancer with hepatic metastases who are candidates for systemic treatment.~* Confirmation of metastatic liver disease within one month prior to inclusion in one of the following radiological procedures:~  * Contrast-enhanced spiral computed tomography showing at least one liver nodule ≥ 20 mm in longest diameter according to RECIST 1.1 criteria~ * MR imaging of the liver with liver lesions suspicious for metastases~ * PET computed tomography (PET/CT) with liver lesions suspicious for metastases~* Patient is eligible and designated for treatment with standard-of-care first-line bevacizumab-containing, fluoropyrimidine-based chemotherapy.~* ECOG performance status ≤ 2 (see appendix)~Exclusion Criteria:~* Inability or unwillingness to comply with the participation requirements~* History of untreated hyperthyreosis~* History of intolerance of or allergy to iodine contrast media according to CTCAE V4.03~* Calculated creatinine clearance \< 45 ml/min~* For fertile women: positive urine pregnancy test or lactation.~* Known or suspected non-compliance, drug or alcohol abuse~* Life expectancy of less than 3 months~* Participation in another interventional trial with an investigational medicinal product (IMP) and within 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perfusion-computed tomography (CTP) (Type: OTHER): Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Versus Sulphonylurea in Type 2 Diabetes During Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Muslim men and women with Type 2 diabetes.~2. Age 18-78 years~3. Intending to fast during the month of Ramadan~4. On oral antihyperglycemic agents (sulphonylurea based/combination therapy)~Exclusion Criteria:~1. Patient with hypersensitivity or contraindication to Sitagliptin treatment~2. Patient with CKD (creatinine clearance \<50 ml/min)~3. Patients who have participated in another intervention study in the last 2 months~4. Patients who do not give informed consent~5. Pregnant or breast feeding women.~6. Patients on insulin~7. Patients with severe liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Sitagliptin 100mg
- 2 (Type: ACTIVE_COMPARATOR): Sulphonylurea

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Extranodal NK/T-cell lymphomas~2. Confirmed pathological diagnosis by the Department of Pathology SGH/NUH/TTSH.~3. Age more than or equals to 21 years.~4. Stages IB or bulky disease, II - IV~5. ECOG performance 0-2~6. Laboratory tests: ANC more than or equals to 1000/mm3, platelet more than or equals to 75,000/mm3. Creatinine less than or equals to 2x ULN or creatinine clearance more than or equals to 50 ml/min; AST and ALT less than or equals to 3x ULN. Total bilirubin \< 1.5x ULN except \< 3x ULN in patients with Gilbert's (as defined as \> 80% unconjugated hyperbilirubinemia without other known cause); unless impairment is due to organ involvement by lymphoma.~7. Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria~1. Had prior systemic chemotherapy. Patients may be entered if they have had prior limited-field radiotherapy or a short course of glucocorticoids or single agent chemotherapy for an urgent local problem at diagnosis (e.g. epidural cord compression, superior vena caval syndrome).~2. History of peripheral neuropathy~3. HIV positive~4. Presence of CNS disease~5. Hypersensitivity to bortezomib, boron, or mannitol~6. Contraindication to any cytotoxic drug contained in the chemotherapy regimen.~7. Female subject of child-bearing potential not willing to use an acceptable method of birth control (i.e. a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and one year beyond treatment completion.~8. Female subject pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotrophin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for women without child-bearing potential.~9. Invasive or active malignancy in past 2 years.~10. Serious concomitant medical illnesses that would jeopardize the patient's ability to receive the regimen with reasonable safety.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early stage (IB or bulky disease - II) (Type: EXPERIMENTAL): who will receive GIFOX-B chemotherapy followed by involved field radiotherapy.
- Advanced stage (III - IV) (Type: EXPERIMENTAL): will receive only chemotherapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with the diagnosis of:~  * De novo acute myeloid leukaemia in first or second remission.~ * Secondary acute myeloid leukaemia in first or second remission supervening after myelodysplastic syndrome or cytotoxic / immunosuppressive therapy.~ * Acute lymphoblastic leukaemia in first or second remission.~ * Myelodysplastic syndrome.~ * Chronic myeloid leukaemia, patients who are candidate for SCT.~ * Malignant lymphoma following relapse or first line therapy resistant.~ * Aggressive mantle cell lymphoma in first complete remission.~* Age 18-65 years.~* WHO performance 0-1 (see appendix ).~* Availability of an HLA-identical sibling or HLA, A, B, DRB, DQB -identical VUD donor.~* Life expectancy \> 3 months.~* Witnessed written informed consent.~Exclusion Criteria:~* Patients with severe cardiac dysfunction (NYHA-classification II-IV)~* Patients with severe pulmonary dysfunction (vital capacity or diffusion \< 70% of predicted value).~* Patients with hepatic dysfunction, bilirubin or transaminases \> 2.5 x upper normal limit~* Patients with renal dysfunction, serum creatinin \> 150 umol/liter or clearance \< 40 ml/minute.~* Patients with a history of moderate ore severe CNS disturbances and psychiatric problems.~* Prior treatment with chemotherapy, immunotherapy, radiation therapy or surgery within the last 3 weeks before entering the study.~* Patients with active uncontrolled infections.~* Patients who are poor medical risks because of non malignant systemic disease.~* Patients with severe coagulopathy.~* Patients to be known HIV positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Fluid Therapy in Sepsis by a Passive Leg Raising Test

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All patients \>18 years admitted to the ICU diagnosed with circulatory shock due to suspected sepsis or pancreatitis. Circulatory shock is defined as MAP\<70 mm Hg or need for norepinephrine despite resuscitation with ≥30 ml/kg of crystalloid fluids.~Exclusion Criteria:~\> 12 hours have passed after onset of shock. The patient has contraindications for an arterial femoral/axillary line. Elevated ICP. Patients who have had a femoral amputation. Elevated intraabdominal pressure\>20 cm H2O.~Suspension criteria: The patient has developed pulmonary oedema during PLR test. Life threatening bleeding.~Serious adverse events:~Trombosis in arteria femoralis. Death during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Passive Leg Raising (Type: EXPERIMENTAL): Before decision on fluid administration a passive leg raising test is performed. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
- Standard of care (Type: ACTIVE_COMPARATOR): Patients are treated according to Surviving Sepsis Guidelines. Fluid is administered according to the choice of the clinician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Women aged ≥18 years diagnosed with histologically verified CIN 3 and women aged ≥ 30 years diagnosed with CIN 2~2. Satisfactory colposcopy~3. Signed informed consent~4. Negative pregnancy test~5. Appropriate contraception method for fertile women during active study period~6. Adequate compliance~Exclusion criteria:~1. Adenocarcinoma in situ~2. History of previous conization~3. Malignant disease at the time of inclusion~4. Colposcopy suspicious for invasive disease~5. Pregnancy and lactation period~6. Known allergy or intolerance to IMQ~7. Contraindications to conization or IMQ~8. Symptoms of a clinically relevant disease~9. Known HIV infection~10. Evidence of a clinically significant immunodeficiency~11. Current, reported participation in another experimental, interventional protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Imiquimod (Type: EXPERIMENTAL): 16 weeks topical Imiquimod
- Conization (Type: ACTIVE_COMPARATOR): Large loop excision of the transformation zone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who have given written informed consent to participate in the study.~2. Type 2 Diabetes Mellitus patients either Male or female from 18 - 75 years of age (both inclusive).~3. Patients who are uncontrolled on metformin monotherapy for at least past 4 weeks (1000-1500 mg daily and HbA1c \> 7.5 - 9%).~4. Patients with HbA1C levels within the range \> 7.5% - 9%. (If a past value is available within the last 12 weeks, it would be considered acceptable provided it was obtained after at least 4 weeks of metformin therapy 1000-1500 mg daily).~Exclusion Criteria:~1. Age \> 75 years ; BMI \<22 or \>40 kg/m2~2. Patients who are on Insulin therapy at the time of study entry.~3. Type 1 Diabetes Mellitus patients.~4. Patients with severe renal (creatinine clearance \< 50 ml/min) or hepatic impairment (including pre-treatment ALT or AST \> 3 x ULN).~   Creatinine clearance will be estimated from serum creatinine using Cockcroft-Gault formula (Cockcroft and Gault, 1976)~5. Patients with contraindications as mentioned in the Summary of Product Characteristics (SPCs) for vildagliptin, metformin, glimepiride, vildagliptin plus metformin and glimiperide plus metformin.~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A: Vildagliptin plus metformin (Type: EXPERIMENTAL): Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
- Group B: Glimepiride plus metformin (Type: ACTIVE_COMPARATOR): Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Choroidal Thickness in Optic Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* age greater than 18 years,~* diagnosis of optic neuropathy,~* willing and able to sign an informed consent.~Exclusion criteria:~* steroid use within the past 4 weeks,~* inability to cooperate with optical coherence tomography (OCT) testing,~* relevant ocular comorbidities in the affected or unaffected eye, such as~  * glaucoma,~ * uveitis,~ * optic nerve hypoplasia,~ * age related macular degeneration,~ * refractive error greater than 5 spherical diopters.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria for GERD patients are:~* Symptomatic heartburn~* Regurgitation~* Chest pain or water brash~Exclusion Criteria:~Exclusion criteria for normal volunteers include:~* Medications-Subjects on any medication which could effect the gastroesophageal junction high-pressure zone will be excluded, this includes use of antacids, H2 blockers, proton pump inhibitors, prokinetic agents, erythromycin type antibiotics and anticholinergics.~* GI symptoms, conditions and disorders~In addition exclusion criteria will include a history of:~* Esophagitis~* Gastrointestinal symptoms such as abdominal pain~* Heartburn~* Reflux~* Regurgitation~* Chest pain~* Difficulty swallowing~* Pain on swallowing~* Dysphagia~* Abdominal surgery involving the stomach or esophagus~* Nausea or vomiting~* Diabetes~* Scleroderma~* Esophageal motility disorders~* Non cardiac chest pain~* Achalasia and current pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Normal Control (Type: None): Normal control subjects are the participants with no history of GERD, no signs and symptoms of GERD
- GERD Patients (Type: None): GERD patients are those with history of GERD, signs and symptoms of GERD and selected signs and symptoms of GERD in the questionnaire.
- Barrett's patients (Type: None): Barrett's patients are those participants who in addition to all the qualities of GERD patients have long standing history of GERD and mucosal changes in the esophagus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quaternary Ammonium and Immunization in Hairdressers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Being at least 16~* Being regularly registered in a Hairdressing school in first and second year~* Mastery of French language~Exclusion criteria :~* No French speaking parents for underage students~* People under legal guardianship~* French special Health Insurance for non-residents (AME)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- First year students (Type: OTHER): Students in their first year of Hairdressing School
- Third year students (Type: OTHER): Students in their third year of Hairdressing School

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet criteria for diagnosis of CRS with nasal polyps undergoing medically indicated sinus surgery~Exclusion Criteria:~* cystic fibrosis~* aspirin exacerbated respiratory disease~* uncontrolled or unstable chronic diseases such as uncontrolled diabetes~* active or history of cancer~* HIV positive~* history of liver or kidney disease~* history of disease with effects on immune system~* pregnant~* allergy to triazole antifungals

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 2 capsules by mouth twice a day for 24 weeks
- Itraconazole (Type: ACTIVE_COMPARATOR): Two 100mg capsules by mouth twice a day for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has completed study 3133K1-3001 (Week 78) and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease~* Mini-Mental Status Examination (MMSE) \>=10 at screening~* Caregiver able to attend all clinic visits with subject~Exclusion Criteria:~* Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.~* Any significant brain MRI abnormality.~* Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Bapineuzumab 0.5 mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Neurostimulation in Chronic and Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients from age 18 upwards (max. 80 years) suffering from chronic or episodic migraine. Medication overuse headache (MOH) patients are included as well (as chronic migraine patients do often show MOH).~Healthy volunteers (18-80 years) are included if they don't fulfil the exclusion criteria and do not suffer from migraine or other headache disorders, except infrequent episodic tension-type headache All volunteers are able to read and sign the informed consent.~Exclusion Criteria:~Patients and healthy volunteers are excluded if they fulfil one of the following exclusion criteria:~Common MR exclusion criteria: such as metallic items in the body (i.e. eye splinter, MR incompatible implants\*), pacemaker, claustrophobia or obesity (body mass index \> 35).~Also pregnant participants and participants suffering from a degenerative disorder of the Central Nervous System, such as Stroke, Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease and Huntington's Disease will be excluded. Participants with major psychiatric disorders such as schizophrenia, bipolar disorder will also be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Real Neurostimulation (Type: EXPERIMENTAL): 4 weeks of neurostimulation (using tDCS)
- Sham Neurostimulation (Type: SHAM_COMPARATOR): 4 weeks of sham Treatment with the same device used for real neurostimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues